News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
SpyGlass Pharma (SGP) reported a net loss of $(19.9) million, or $(0.59) per diluted share, for the second quarter of 2026, as the company continues to invest in development and scale-up activities. The company, which has no product revenue since inception, saw its net …
SpyGlass Pharma (SGP) reported a Q2 2026 net loss of $19.9 million and held $234.2 million in cash and investments. The company is advancing its BIM-IOL Phase 3 trials and preparing for a first-in-human study for the BIM-DRS, with enrollment for BIM-IOL expected to …
SpyGlass Pharma, Inc. (SGP) released its Quarterly Earnings Report (Form 10-Q) for the period ended June 30, 2026. The company reported $234.2 million in cash and short-term investments after its IPO, but expects to need future capital for its operations, which are projected to …
SpyGlass Pharma reported a Q2 2026 net loss of $19.9 million but maintains a strong cash position of $234.2 million, expected to fund operations through 2028. Enrollment for its Phase 3 BIM-IOL System trials remains on schedule for completion in 2027, and the company …
Insiders at SpyGlass Pharma (NASDAQ:SGP) who invested US$2.16 million in shares over the past year have seen their investment appreciate by US$1.1 million, now valued at US$3.25 million. This 51% gain followed a 10% increase in the company's market worth last week. The largest …
This article announces that 22,536,164 shares of common stock of SpyGlass Pharma, Inc. (SGP) are under a lock-up agreement. The lock-up period began on February 5, 2026, and will end on August 5, 2026, lasting 181 days. During this time, company insiders, directors, and …
This article first appeared on GuruFocus. Revenue: Group sales increased 5.1% (4.5% at constant exchange rates) to EUR18.3 billion. EBITDA: Increased 7.6% to EUR1.2 billion, with a margin of 6.8%, up 16 basis points year-over-year. Net Cash Position (ex-IFRS 16): EUR11 million as of …
This article first appeared on GuruFocus. Full Year EBITDA Guidance: Updated to circa EUR 4 billion. Operating Cash Flow Guidance: Updated to EUR 3 billion. Dividend Per Share: Proposed 10% increase to $0.70. Renewables EBITDA: Pro forma renewables EBITDA to roughly $110 million for …
Spyglass Pharma's shares gapped up at market open, rising to $21.80 from a $20.88 close, settling around $21.26. Despite a "sell" downgrade from Wall Street Zen, MarketBeat maintains a "Moderate Buy" rating with a $45.00 price target. The company recently missed Q1 earnings estimates, …
The article provides a basic overview of SpyGlass Pharma, Inc. (SGP) on TradingView, focusing on its financial data and market information. It highlights that no trades were made and offers general information about the company's financial statements, statistics, dividends, earnings, and segments. The content …
SpyGlass Pharma (SGP) presented at the Jefferies Global Healthcare Conference 2026, highlighting its strategic vision for a BIM-IOL system that combines intraocular lens implantation with multi-year drug elution to treat cataracts and glaucoma. The company aims for a 2029 commercial launch, with ongoing Phase …
Search by ticker symbol or company name and select a result to open its chart.